David Myles Biography and Net Worth

Chief Discovery and Non-Clinical Development Officer of Olema Pharmaceuticals

Dr. Myles joined Olema Oncology in April 2008 and currently serves as Chief Discovery and Non-Clinical Development Officer. He originally joined the company as Executive Vice President, Drug Discovery and Development, to start medicinal chemistry efforts and was promoted to Chief Development Officer in 2020. Before that, he co-founded and served as Chief Operating Officer of Epiphany Biosciences, Inc. Previous positions include Executive Director of Chemistry at Kosan Biosciences, Inc.; Associate Director of Medical Chemistry at Chiron Corporation; and Assistant Professor in the Department of Chemistry and Biochemistry at the University of California, Los Angeles. Dr. Myles received a B.A. in chemistry from Occidental College and a Ph.D. in chemistry from Yale University. He was a National Institutes of Health (NIH) postdoctoral fellow at Harvard University.

What is David C. Myles' net worth?: The estimated net worth of David C. Myles is at least $16.95 million as of December 10th, 2024. Dr. Myles owns 611,947 shares of Olema Pharmaceuticals stock worth more than $16,945,424 as of December 4th. This net worth estimate does not reflect any other assets that Dr. Myles may own. Additionally, Dr. Myles receives an annual salary of $200,000.00 as Chief Discovery and Non-Clinical Development Officer at Olema Pharmaceuticals. Learn More about David C. Myles' net worth.
How old is David C. Myles?: Dr. Myles is currently 61 years old. There are 4 older executives and no younger executives at Olema Pharmaceuticals. Learn More on David C. Myles' age.
What is David C. Myles' salary?: As the Chief Discovery and Non-Clinical Development Officer of Olema Pharmaceuticals, Inc., Dr. Myles earns $200,000.00 per year. There are 4 executives that earn more than Dr. Myles. The highest earning executive at Olema Pharmaceuticals is Dr. Sean P. Bohen M.D., Ph.D., President, CEO & Director, who commands a salary of $1,150,000.00 per year. Learn More on David C. Myles' salary.
How do I contact David C. Myles?: The corporate mailing address for Dr. Myles and other Olema Pharmaceuticals executives is 512 2ND STREET 4TH FLOOR, SAN FRANCISCO CA, 94107. Olema Pharmaceuticals can also be reached via phone at 650-243-5555 and via email at [email protected]. Learn More on David C. Myles' contact information.
Has David C. Myles been buying or selling shares of Olema Pharmaceuticals?: David C. Myles has not been actively trading shares of Olema Pharmaceuticals within the last three months. Most recently, David C. Myles sold 12,452 shares of the business's stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $9.38, for a transaction totalling $116,799.76. Following the completion of the sale, the insider now directly owns 611,947 shares of the company's stock, valued at $5,740,062.86. Learn More on David C. Myles' trading history.
Who are Olema Pharmaceuticals' active insiders?: Olema Pharmaceuticals' insider roster includes Sean Bohen (CEO), Cyrus Harmon (CTO), Kinney Horn (Insider), David Myles (Chief Discovery and Non-Clinical Development Officer), and Naseem Zojwalla (Chief Medical Officer). Learn More on Olema Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Olema Pharmaceuticals?: During the last twelve months, Olema Pharmaceuticals insiders bought shares 1 times. They purchased a total of 300,000 shares worth more than $1,728,000.00. During the last twelve months, insiders at the sold shares 8 times. They sold a total of 798,797 shares worth more than $5,619,449.23. The most recent insider tranaction occured on September, 18th when Director Cyrus Harmon sold 10,000 shares worth more than $83,300.00. Insiders at Olema Pharmaceuticals own 16.4% of the company. Learn More about insider trades at Olema Pharmaceuticals.
Information on this page was last updated on 9/18/2025.

David C. Myles Insider Trading History at Olema Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/10/2024	Sell	12,452	$9.38	$116,799.76	611,947
11/8/2023	Sell	200	$17.61	$3,522.00	561,270
11/3/2023	Sell	541	$17.51	$9,472.91	561,470
11/1/2023	Sell	6,668	$15.02	$100,153.36	565,343
9/19/2023	Sell	20,000	$12.67	$253,400.00	572,011

David C. Myles Buying and Selling Activity at Olema Pharmaceuticals

Olema Pharmaceuticals Company Overview

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Today's Range

Now: $27.64

$26.93

$28.45

50 Day Range

MA: $13.44

$7.77

$28.12

2 Week Range

Now: $27.64

$2.86

$29.51

Volume

2,861,447 shs

Average Volume

7,644,495 shs

Market Capitalization

$1.90 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.87

David Myles Biography and Net Worth

What is David C. Myles' net worth?

How old is David C. Myles?

What is David C. Myles' salary?

How do I contact David C. Myles?

Has David C. Myles been buying or selling shares of Olema Pharmaceuticals?

Who are Olema Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Olema Pharmaceuticals?